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Letters to the Editor260omentum, driven by the extensive datasets on better radial access
utcomes to encourage the next generation of interventionalists to
tep to the front of the world’s stage in patient care.
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henotypes, Genotypes, and the
p21 Locus for Prediction of
ardiovascular Events
would like to commend Hoppmann et al. (1) for their thorough
nd well-executed paper. In this regard, I agree with the editorial
y Horne and Anderson (2) that discusses the importance of the
oppmann et al. (1) study. Thoughtfully executed prospective
tudies that attempt to clinically examine genomic data first
dentified in genome-wide association studies are at a premium.
Other remarks in the editorial by Horne and Anderson (2) are
source of disagreement. First, the authors make the argument
hat because replications of the 9p21 single nucleotide polymor-
hisms (SNPs) have been done in populations that suffer from
oth documented coronary artery disease (CAD) and myocardial
nfarction (MI), these individual phenotypes—when grouped to-
ether—confound the type of risk (phenotype) that can be
ttributed to these genetic factors. Although their argument is
nderstood, it is important to point out that on the basis of
xperience, these genetic markers are statistically significant in
oth subpopulations to sometimes nearly equal extent. These data
re sometimes not shown in final reports and are only rarely shown
n supplemental data. The authors then attempt to differentiate the
athogenesis of CAD and that of MI as 2 distinct entities, which
urther precludes attribution of genetic risk to either of those 2
henotypes individually. It is difficult to assume that the well-
nown progression of CAD to MI (barring less usual suspects such
s spasm or dissection) can be so thoroughly extricated from each
ther as to invalidate the dozens of studies that have replicated the
p21 locus as a risk marker for CAD and MI.
The authors then make the argument that because the study by
oppmann et al. (1) finds there to be a negative association
etween restenosis and these genomic markers, restenosis must be idistinct pathophysiologic entity from CAD because it is not
driven” by genetic factors at 9p21.3. Though this might be the
ase as evidenced by much work in cell biology and immunology,
n assumption based on 1 prospective clinical study that examined
SNPs is difficult to accept. Additionally, it should be noted that
he 4 SNPs tested by Hoppmann et al. (1) are not the most
requently validated SNPs for 9p21 but rather an amalgam of
NPs from different studies that first identified the variants. This
s possibly due to the initiation of the 3-year prospective study
efore replications of the more popular variants in better-
haracterized populations.
It is certainly necessary to temper our enthusiasm for direct-to-
onsumer genetic testing until these markers can be better under-
tood, a point of agreement with Horne and Anderson (2). In the
nterim, we should encourage more studies such as the one
resented by Hoppmann et al. (1) and continue our emphasis on
reventative cardiovascular medicine.
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eply
e would like to thank Dr. Abdullah for the remarks regarding
ur editorial (1). We appreciate the subtleties of our assertions and
cknowledge that the important biological distinctions among
yocardial infarction (MI), coronary artery disease (CAD), and
estenosis might be unfamiliar. We appreciate the opportunity to
larify our arguments.
It was not our intent to claim that prior studies associating
p21.3 with MI risk are invalid but to say that some erroneous
onclusions about pathophysiological implications for coronary
eart disease were drawn from those landmark studies. Because
estenosis is a different process than CAD (2), our intent also was
o note that 9p21.3 is not involved in its distinctive pathophysi-
logy (1).
A major component of our argument is, in fact, that 9p21.3
ingle nucleotide polymorphisms “are statistically significant in
oth subpopulations to sometimes nearly the same extent.” To
llustrate, consider 1 European study that showed a similar effect
